PLX-4720

For research use only.

Catalog No.S1152

147 publications

PLX-4720 Chemical Structure

CAS No. 918505-84-7

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 477 In stock
USD 670 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PLX-4720 has been cited by 147 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 M3H5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\BeGlEPTB;MD6wO|Q2PyEQvF2= NEPqSnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
EoL-1-cell NFTzb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO4SYJKSzVyPUCuNVQyPjZizszN MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
C32 M1:zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLaTWM2OD1yLkG1NVMyKM7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
M14 M1[5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED6do5KSzVyPUCuNlE4PTdizszN M2LBUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
CP50-MEL-B M1jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\tRmlEPTB;MD6yPVc5PCEQvF2= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
A101D MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXzTWM2OD1yLkOyOVg6KM7:TR?= NGfpb4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
G-361 NF;nXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ToRmlEPTB;MD6zOFY{PyEQvF2= NYrZcYJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
HT-144 NXriOXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwM{[zNlkh|ryP Mn7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
ACN MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3yTWM2OD1yLkO4OFc4KM7:TR?= NV73UpRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
COLO-829 NGTPU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\o[GlEPTB;MD6zPFk3QCEQvF2= NIDL[mc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
MEL-HO MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDSHB{UUN3ME2wMlQyOTd7IN88US=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SH-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:0bo5wUUN3ME2wMlQyPDJ{IN88US=> NIP4[WQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
SK-MEL-3 NXvZeIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;IfIxSUUN3ME2wMlUyPTZ6IN88US=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
A375 M1XLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjaTWM2OD1yLk[3N|U6KM7:TR?= NEDz[oc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
MMAC-SF MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jxXWlEPTB;MD62PFYyPCEQvF2= MnLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
BHT-101 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC4PWxCUUN3ME2wMlcxPzB{IN88US=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
K5 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwN{[xOFgh|ryP M4XDUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
BV-173 NY\OS3dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwN{m2OFQh|ryP NHOx[m89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
RVH-421 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSzSXlKSzVyPUCuPFY4QTZizszN MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HCC2218 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwOEe4OFQh|ryP Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
WM-115 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\1NWQ4UUN3ME2wMlg5Pjl{IN88US=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SK-MEL-28 NYrFXoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPYOo5bUUN3ME2xMlA1PTZ7IN88US=> NIeyeFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
COLO-679 NX\helQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PrWmlEPTB;MT6xNFQ3PCEQvF2= M1G1c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
MZ7-mel NHrPZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwMUS5OlMh|ryP NHvHems9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
SK-MEL-30 NWe0[VAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLlWXBDUUN3ME2xMlM{Ozh4IN88US=> NGXodGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
NCI-H209 NYfYb4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwNkC4OkDPxE1? NVPmUXdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
HTC-C3 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwNk[yPVQh|ryP MlnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
KARPAS-45 NFr4TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJwMES5O|gh|ryP M3[1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-SNU-5 M2i3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nQRmlEPTB;Mj6xNVk3QSEQvF2= MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
KP-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDITWM2OD1{LkOwO|g4KM7:TR?= Ml;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
PA-1 NHfwXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITNRWNKSzVyPUKuO|I3PzNizszN M3G5Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
HuO-3N1 NGP0WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2OWlEPTB;Mj64O|k1PiEQvF2= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-H358 NVHhb49YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O1e2lEPTB;Mj65NlI{OiEQvF2= NFK5OHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
CTB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn30TWM2OD1|LkSwNVc3KM7:TR?= M1f6eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
697 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T3cGlEPTB;Mz61OVI3PiEQvF2= NX25OpdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
CP66-MEL NXzzNVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMUW5Nlch|ryP NIqwe2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
NB13 NVTZTGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4WW5yUUN3ME20MlQ6OTd7IN88US=> MnPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
DBTRG-05MG NFHjRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTRwNUOzNlUh|ryP MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
A2058 NXTHcGxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LhNGlEPTB;ND63NlE3PCEQvF2= NUjTcVVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
KG-1 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ITWM2OD12LkezPVA5KM7:TR?= MlHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
8305C NXq1UG9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\Kdm5RUUN3ME21MlE5PzNizszN M3X5N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
RPMI-7951 NIrVbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;zS3hPUUN3ME21MlgxOjh|IN88US=> MorVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
CHL-1 NVjTbXZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDiSJhbUUN3ME21Mlk4PjB|IN88US=> NX3FS5JQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
TI-73 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjGW4ZKSzVyPU[uNFA6ODJizszN MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HT-1080 NVjiToIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTZwMUC5OFYh|ryP MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
ES5 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTZwMUS5NlQh|ryP NVr0bpBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
8-MG-BA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD14LkG4NVI6KM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NB7 NFnOOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWToWGJ1UUN3ME22MlIyOzd|IN88US=> NX7ob4ppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
H4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTZwMkK0PVMh|ryP MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
CAL-72 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwNEW0NlMh|ryP MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HCC1806 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZwOEG5N|Eh|ryP MlmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
BCPAP NF7z[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XofGlEPTB;Nz6yNVc3PCEQvF2= NI\JUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
LB2241-RCC NXHyUWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwM{[5NFch|ryP M1LsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
COLO-741 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fNdmlEPTB;OD6wNVY4QSEQvF2= M{WxbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
HSC-3 NH73bWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHyc5BKSzVyPUiuNFcxPjhizszN NUfsVnpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SW982 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrRTWM2OD16LkSxOVE3KM7:TR?= NXTBRm54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
GCT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{noeWlEPTB;OD63OVMyPCEQvF2= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
KY821 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfxTWM2OD17LkC1NVc5KM7:TR?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
JVM-3 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DjSmlEPTB;OT61Olk6QSEQvF2= NWnuSlVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
RS4-11 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTlwNkC0PEDPxE1? NHra[Ys9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
VA-ES-BJ M3LZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHtRndKSzVyPUGwMlAyPDlizszN M4DGbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
A431 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDyTWM2OD1zMD60NlEzKM7:TR?= NXjsSG5zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
LXF-289 NFfQZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDOc2x7UUN3ME2xNE41PThizszN NXntd3pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SK-MEL-24 M{fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXYeXVbUUN3ME2xNE45Ojd2IN88US=> M1H2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NOS-1 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ETWM2OD1zMD64OFczKM7:TR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
KNS-62 M{P3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFzLkK0NFQh|ryP MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SK-HEP-1 NWPNNmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFzLkO1Nlch|ryP M3LwV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
A3-KAW NGfn[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjGTJc3UUN3ME2xNU44OTd6IN88US=> NGTuR5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
SK-LU-1 M4L5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF{LkK2OVUh|ryP NH7mcGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
TYK-nu NIH1[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nQeGlEPTB;MUKuN|k{OiEQvF2= Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
NMC-G1 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrlNWc2UUN3ME2xNk43ODZ{IN88US=> MknPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
BB65-RCC NYnMUVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHj[IVnUUN3ME2xNk44OTZ7IN88US=> NWL5bmgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
QIMR-WIL NFqzZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF{Lki4N|Mh|ryP MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
D-566MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PLVWlEPTB;MUOuPVU4PiEQvF2= Mo\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
KYSE-140 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHGbFlKSzVyPUG0MlA4PTNizszN MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SCC-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3mVJFQUUN3ME2xOE4{OzV7IN88US=> NV;ZSFU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
U251 M{Xle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjPblhzUUN3ME2xOE45PDl{IN88US=> MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
D-542MG MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;pfWlEPTB;MUSuPVIzOiEQvF2= M4jXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LAMA-84 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLNU|QzUUN3ME2xOE46QTN{IN88US=> M{PJS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H720 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fXeGlEPTB;MUWuNlY5PCEQvF2= M3\FXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
DEL MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT1TWM2OD1zNT60Nlk{KM7:TR?= NYX3dJViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SBC-1 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO3THpKSzVyPUG1MlQ{ODVizszN M3fBcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
ECC10 NGTqO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xle2lEPTB;MUWuOFQ2QCEQvF2= M1LLc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
Daoy Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVThNVRbUUN3ME2xOU44PjF4IN88US=> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SCH MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXCTWM2OD1zNT63PFM2KM7:TR?= NUXoSXMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
MZ2-MEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;lR2VNUUN3ME2xOk4xPjR4IN88US=> NXjhVlFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
CAL-12T MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GxRWlEPTB;MU[uOFg3OiEQvF2= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
KE-37 M4C1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fTWmlEPTB;MU[uPFExPyEQvF2= NGXDOlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
LS-411N MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSyTWM2OD1zNz6xNVgh|ryP M{jxbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H2228 NUnjd4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPpU5pKSzVyPUG3MlMxPzFizszN NWSyZmJzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SK-MEL-2 M4TsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPaS2dKSzVyPUG3MlQ6PjVizszN MkLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PWXmlEPTB;MUeuO|I1QCEQvF2= M3PG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H1648 NVP4T4xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\wTWM2OD1zNz64NVgh|ryP NIm4T2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
IA-LM M{nyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF6LkOxO|Ih|ryP NGDpO4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
EW-13 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXtVnVMUUN3ME2xPE42PzB6IN88US=> NIXPU5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
YKG-1 M1jGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULndY92UUN3ME2xPU42PzFzIN88US=> M2f6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
KNS-81-FD NWPCfVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33mR2lEPTB;MUmuOVg2QCEQvF2= M{mxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
23132-87 NEDQfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF7Lke2OFIh|ryP M{[yTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NUGC-3 NGDLfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXZTWM2OD1zOT65PFg4KM7:TR?= MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
5637 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJyLkC0O|gh|ryP NV;kRlg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H1755 NVn3bYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHntSGNKSzVyPUKwMlQ4PjRizszN NFPkRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
RH-18 M1v0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwVo9KSzVyPUKwMlU4PDhizszN M4HvUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
RXF393 NHvYV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJyLk[3OVYh|ryP M3;RUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LU-134-A Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJyLkewOVYh|ryP NHT4XmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
TE-12 M4[1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJyLkeyNFEh|ryP NVjuZmJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvLWWNRUUN3ME2yNU4yQTF3IN88US=> M4LEclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
IGR-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLYTWM2OD1{MT6zO|k3KM7:TR?= MlvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HOP-92 NGPjRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJzLkS5PFch|ryP MkDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
SK-MES-1 NEnFcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnRR2w5UUN3ME2yNU44OzhzIN88US=> MlTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LU-65 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDLTWM2OD1{MT64OlI1KM7:TR?= NYTiRnJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
MS-1 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ{LkGyNFMh|ryP MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LoVo NHHDc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ{LkK0OEDPxE1? Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
A704 NX;CdYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHQVYFiUUN3ME2yNk42OTV3IN88US=> NIPVSJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HT-1376 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz3eJBKSzVyPUKyMlYxPTlizszN MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
IST-MEL1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvibZBKSzVyPUKyMlY4PTFizszN MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXKUnV[UUN3ME2yNk44OzZ4IN88US=> NHPobG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
T47D MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHhXYFKSzVyPUKyMlc6PzlizszN MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HT-1197 NVX2VnoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ|LkC4NVch|ryP MlrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LB2518-MEL NUnUbJFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK0fWJKSzVyPUKzMlY1OTJizszN MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfQe3RKSzVyPUK0Mlc2QTVizszN NHrTSHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
SK-NEP-1 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKzTWM2OD1{ND64O|Q1KM7:TR?= NWG3bohPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H526 NH7tT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XF[mlEPTB;MkWuNFAzOyEQvF2= NGewN|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
IST-SL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTKTWM2OD1{NT6yO|UyKM7:TR?= NF\PcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HH NFPzTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ3LkOxPVIh|ryP NXrseI9WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H82 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLpOZRKSzVyPUK1Mlk{QCEQvF2= NV25dpZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SNU-449 NULCNoVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfzRZVvUUN3ME2yO{4zODF6IN88US=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
COR-L23 NVrVToI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjmTVVKSzVyPUK3MlI5OTNizszN M1jKNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LOXIMVI NUi3XmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO4XpdOUUN3ME2yO{4{PjhizszN MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
GR-ST MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ5Lk[3NFYh|ryP M13PfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-SNU-1 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ5Lkm0OEDPxE1? NFjnVVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
ALL-PO M2fsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TrbGlEPTB;MkiuNVYxPCEQvF2= Ml3wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
ML-2 M2nSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC5VoVKSzVyPUK4MlI5OTRizszN NHjiNnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HOP-62 NGLVNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ6LkexN{DPxE1? MoS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
EGI-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ6Lki4OFUh|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
TCCSUP Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTFTWM2OD1{OD65NlczKM7:TR?= Mn;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LB996-RCC MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzHcJdKSzVyPUK5MlU3QDJizszN NU\DNmo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
LCLC-97TM1 NVTZdYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzoTWM2OD1|Mj6xPVY1KM7:TR?= NXrZb5N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H1304 NV3qdmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPYXIc1UUN3ME2zNk4{OzBzIN88US=> NFXGT2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
KP-N-YS MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;rfmtKSzVyPUOyMlU6PzNizszN MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-H1770 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPSTWM2OD1|Mz6xOlQ5KM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
EM-2 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXZO|lKSzVyPUOzMlY2ODRizszN MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
ChaGo-K-1 NGnCUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP4b|EzUUN3ME2zN{44OjN4IN88US=> MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
ACHN NGDybYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN|LkizPFUh|ryP NIG4dVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
MN-60 M3HlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfQPIlFUUN3ME2zN{45PTR2IN88US=> NWLt[ZhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
EW-18 M1HnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN|Lki5O|Eh|ryP NYnBfJQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
KGN NUf4fYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[2SWdtUUN3ME2zOU44Ojl{IN88US=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
U031 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN3LkixN|Ih|ryP MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HMV-II NUHSZXdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX0VVRxUUN3ME2zOk4xPzd2IN88US=> MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
L-363 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfQTWM2OD1|Nz62OFU2KM7:TR?= MonaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
NCI-H1155 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN6LkCwNVUh|ryP MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-H1793 NGr6OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN6LkGwNlYh|ryP NVn1PVhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
P30-OHK NFjON|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnidIZGUUN3ME2zPE4yOzN{IN88US=> M3;UWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
AN3-CA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzuO3htUUN3ME2zPE4yPjF3IN88US=> M3G1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
UACC-257 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;xTWM2OD1|OD63PUDPxE1? M4DMNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
MCF7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrzTWM2OD1|OT64OlI6KM7:TR?= NWfNTVJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
KP-N-YN MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13wT2lEPTB;NECuOFI5PSEQvF2= NVewVGZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
T98G MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX32foJ[UUN3ME20NE41QTV5IN88US=> Mo\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HGC-27 M4jOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO0TWM2OD12Mz6yO|Qh|ryP MkW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
NCI-H1092 NV[3O5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXiNXMyUUN3ME20N{4zQDl3IN88US=> MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
KARPAS-299 NHezRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy3NG9KSzVyPUSzMlMxPzFizszN MkHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LB1047-RCC MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjNbot3UUN3ME20OE46QTV7IN88US=> NGHqSFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
786-0 M4n1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrJPYM3UUN3ME20OU43PSEQvF2= M{j1N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
HCC2157 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7adVFjUUN3ME20Ok4xOzV7IN88US=> M2rYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NY M2HjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;STWM2OD12Nj6xO|c5KM7:TR?= M4D0e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
EFM-19 M3PhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTiPZhKSzVyPUS2Mlc2OzNizszN NVHJdVNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
EW-16 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7JU2tMUUN3ME20Ok44QDB4IN88US=> MmPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
UM-UC-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHYS49KSzVyPUS2MlgxPTlizszN MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HT-29 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HITmlEPTB;NEeuPFc6OiEQvF2= Mmn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LN-405 M3SxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR6LkC4Nlch|ryP M1nnTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H727 NWrxNmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofyTWM2OD12OD63O|I3KM7:TR?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
D-502MG NXTZOYYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPON4syUUN3ME20PE46Pjd4IN88US=> NYf4V2ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
GMS-10 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvRWmNwUUN3ME20PU4zQTd2IN88US=> NV\ucW94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
MEL-JUSO MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfqdZptUUN3ME20PU4{PDdizszN NEfqSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
insect cells MVHGeY5kfGmxbjDhd5NigQ>? NYTXUIVXUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqey22YXfn[YQhSlKDRjDWOlAxTSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KGOxLXX4dJJme3OrbnegR2REOzdidYPpcoch[mmxdHnufYxifGWmLV3FT{BieyC|dXLzeJJifGViYomgRYxxcGGVY4Ll[Y4h[XO|YYmsJGlEPTBiPTCwMlAyOyEQvF2u MlzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
A375 MnzJSpVv[3Srb36gZZN{[Xl? NFvUZ5dKdmirYnn0bY9vKG:oIFLSRWYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFGzO|Uh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFXST{BxcG:|cHjvdplt[XSrb36gZpkhSWyyaHHTZ5Jm\W5iYYPzZZktKEmFNUCgQUAxNjB2NDFOwG0v MnyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
A375 MkHKSpVv[3Srb36gZZN{[Xl? NGHoZXRKdmirYnn0bY9vKG:oIHKtVoFnKGmwIHj1cYFvKEF|N{WgZ4VtdHNiYYPz[ZN{\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXST{whUUN3MDC9JFAvODR4IN88UU4> NGPy[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwPFkyOSd-MkK4NFg6OTF:L3G+
A375 MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2P4ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDlfJBz\XO|aX7nJGIuWmGoIG[2NFBGKG23dHHueEBidmRid3ns[EB1gXCnIGLhd{whUUN3MDC9JFAvPSEQvF2u M{\ROFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEC4PVEyLz5{MkiwPFkyOTxxYU6=
A375 M3X1bmN6fG:2b4jpZ4l1gSCjc4PhfS=> NXXNR2NOPzJiaILz MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvPSEQvF2u M{XYPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
HCT116 MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBjNVKjZjDhcoQhU1KDUzDteZRidnRuIFnDOVAhRSB{NzFOwG0v NHvuWI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwPFkyOSd-MkK4NFg6OTF:L3G+
A673 M3f2RpFJXFNiYYPzZZk> M1TsOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MmLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 MlrmdWhVWyCjc4PhfS=> NHXkcY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NEnnVm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NFSzdI1yUFSVIHHzd4F6 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> NGTNVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M4PYZ5FJXFNiYYPzZZk> NV3BZoJbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> M3jFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NWSwTmR4eUiWUzDhd5NigQ>? MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NYTG[lZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M2PqcpFJXFNiYYPzZZk> NWTTN4ZkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NVjJSIJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NGTNXnZyUFSVIHHzd4F6 MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MlfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NVf5N3V7eUiWUzDhd5NigQ>? MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NVG3RmxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MEK / MEK / p-ERK / ERK / p-FAK(S910); 

PubMed: 23076151     


WM793 and WM793-Res NRAS cells were seeded overnight in the absence of PLX4720 and then treated with 1 μm PLX4720 for times ranging from 0 to 24 h. Samples were analyzed by Western blotting for phospho-MEK, total MEK, phospho-ERK1/2, total ERK1/2, phospho-S910 FAK, and total FAK.

p-EGFR 1173 / EGFR / p-Akt / Akt; 

PubMed: 26023796     


Three BRAF(V600E) glioma cell lines, NMC-G1, AM38 and DBTRG-05MG were subjected to a 24 hour time course treatment with 5 μM PLX4720 in the presence or absence of 1 μM HKI-272. These cells were serum starved for 16 hours before being stimulated with 10% FBS and harvested for immunoblotting analysis. Cells treated with PLX4720 alone showed an initial suppression of MEK and ERK phosphorylation followed by a profound rebound of MAPK pathway activation as early as one hour post-PLX4720 treatment. Elevated levels of EGFR phosphorylation were also observed in the PLX4720 treated cells. The extent of Akt phosphorylation increased upon PLX4720 treatment, although the extent varies between cell lines. In contrast, no reactivation of EGFR, MEK, ERK or Akt was observed in cells pre-treated with HKI-272.

p27 / Cyclin D1 / pRb; 

PubMed: 21828154     


Immunoblot analysis revealed that PLX4720 (3 μM) decreased levels of phosphorylated ERK, decreased levels of cyclin D1, increased levels of p27, and decreased levels of phosphorylated Rb in BRAF-mutant (OCM3) cells. On the contrary, in Gα-mutant (OMM1.3) UM cells, PLX4720 induced a paradoxical increase in phosphorylated ERK and Rb levels and an early increase in cyclin D1 levels but did not stimulate p27 levels.

pAkt(Ser473) / pAkt(Thr308); 

PubMed: 21828154     


Immunoblot analysis revealed that both AZD6244 and PLX4720 induced an early (within 2–6 hours of exposure) increase in the levels of phosphorylated Akt (at residues Ser473 and Thr308) in both BRAF-mutant OCM3 and Gα-mutant OMM1.3 cells. Eventually, and with prolonged drug exposure, the phosphorylation of Akt returned to baseline in Gα-mutant OMM1.3 cells and decreased even below baseline levels in BRAF-mutant OCM3 cells.

23076151 26023796 21828154
Immunofluorescence
LAMP1; 

PubMed: 30979895     


Representative images of LysoTracker Red (red) and LAMP1 (green) immunostaining of PLX4720 (1 μM, 12 h-treated) A375 cells with depletion of the indicated genes. Note the reduced lysosome staining in PLX4720-treated cells upon TFEB depletion. 

ZKSCAN3 / TFEB ; 

PubMed: 30979895     


Representative confocal images of subcellular translocation of endogenous TFEB (green) and ZKSCAN3 (red) in A375 cells treated with PLX4720 (1 μM, 12 h). n = 3 independent experiments. 

30979895
Growth inhibition assay
Cell viability; 

PubMed: 27848137     


AM-38 and DBTRG-05MG cells were treated for 5 days. Media was changed once every 3 days. Cell viability was measured using WST-1 assay. Error bars indicate the variation between triplicate measurements. PLX4720 and PD0325901 alone or in combination reduced cell viability significantly. However, combined therapy led to the most significant cell viability reduction compared to either monotherapy in both AM-38 and DBTRG-05MG cell lines.

27848137
ELISA
mIFN-γ; 

PubMed: 23204132     


(C, D and E) IFN-γ secretion by pmel-1 T cells co-cultured with transduced melanoma cells (after cell sorting) that had been pre-treated with the indicated concentrations of PLX4720, as determined by ELISA. (*P<0.05, ** P<0.01) Data are representative of 3 independent experiments.

23204132
In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro Raf kinase activities:

The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:[1]
- Collapse
  • Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 mM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
  • Dosages: 5, 20, or 100 mg/kg
  • Administration: Oral gavage once or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.83
Formula

C17H14ClF2N3O3S

CAS No. 918505-84-7
Storage powder
in solvent
Synonyms N/A
Smiles CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you recommend to make working solution for intraperitoneal injection into mice?

  • Answer:

    PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy PLX-4720|PLX-4720 ic50|PLX-4720 price|PLX-4720 cost|PLX-4720 solubility dmso|PLX-4720 purchase|PLX-4720 manufacturer|PLX-4720 research buy|PLX-4720 order|PLX-4720 mouse|PLX-4720 chemical structure|PLX-4720 mw|PLX-4720 molecular weight|PLX-4720 datasheet|PLX-4720 supplier|PLX-4720 in vitro|PLX-4720 cell line|PLX-4720 concentration|PLX-4720 nmr|PLX-4720 in vivo|PLX-4720 clinical trial|PLX-4720 inhibitor|PLX-4720 MAPK inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID